AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$LGND

Reardon Andrew sold $1.4M of LGND

Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $286.09 ($283.99–$288.98, $1.43M total) across 5 trades on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reardon Andrew
Published Sep 8, 2026, 10:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LGND
Bearish
medium confidence
Mentioned
$LGND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, but the modest size limits market impact.

02

Market read

Primary source filing; modest insider sale may cause slight short‑term price pressure.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 6/10Timing: filed Sep 8, 2026

Background

Form 4 filing provides the first public disclosure of the insider's share sale.

Company-level read

Ticker impact

$LGNDBearishMedium confidence
Context

CLO & Secretary Andrew Reardon sold 5,000 shares for $1.43M via a 10b5‑1 plan on Sep 3, reducing his stake to 36,514 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest relative to market cap, but the insider's senior role and use of a 10b5‑1 plan suggest a neutral to slightly negative impact.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector‑wide.

Regional

No regional effect; the filing is US‑focused.

Global

Limited global relevance.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Ligand Pharmaceuticals Inc.

    Biotech firm listed on NASDAQ under LGND.

  • Executive
    Andrew Reardon

    Chief Legal Officer & Secretary of Ligand Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min
AUG 6
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, F

SEC EDGAR 8-K6 min